Cancer cure for 32 cancer types: results from the EUROCARE-5 study

Luigino Dal Maso, Chiara Panato, Andrea Tavilla, Stefano Guzzinati, Diego Serraino, Sandra Mallone, Laura Botta, Olayidé Boussari, Riccardo Capocaccia, Marc Colonna, Emanuele Crocetti, Agnes Dumas, Tadek Dyba, Silvia Franceschi, Gemma Gatta, Anna Gigli, Francesco Giusti, Valerie Jooste, Pamela Minicozzi, Luciana NeamtiuGaëlle Romain, Manuel Zorzi, Roberta De Angelis, Silvia Francisci, EUROCARE-5 Working Group, Rosa Filiberti

Research output: Contribution to journalArticlepeer-review


BACKGROUND: Few studies have estimated the probability of being cured for cancer patients. This study aims to estimate population-based indicators of cancer cure in Europe by type, sex, age and period. METHODS: 7.2 million cancer patients (42 population-based cancer registries in 17 European countries) diagnosed at ages 15-74 years in 1990-2007 with follow-up to 2008 were selected from the EUROCARE-5 dataset. Mixture-cure models were used to estimate: (i) life expectancy of fatal cases (LEF); (ii) cure fraction (CF) as proportion of patients with same death rates as the general population; (iii) time to cure (TTC) as time to reach 5-year conditional relative survival (CRS) >95%. RESULTS: LEF ranged from 10 years for chronic lymphocytic leukaemia patients to 5 years for women with breast cancer. The CF was 94% for testis, 87% for thyroid cancer in women and 70% in men, 86% for skin melanoma in women and 76% in men, 66% for breast, 63% for prostate and
Original languageEnglish
Pages (from-to)1517-1525
Number of pages9
JournalInternational Journal of Epidemiology
Issue number5
Publication statusPublished - 2020


  • IMP


Dive into the research topics of 'Cancer cure for 32 cancer types: results from the EUROCARE-5 study'. Together they form a unique fingerprint.

Cite this